Now showing items 1-20 of 718

    • Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. 

      Acar, A; Nichol, D; Fernandez-Mateos, J; Cresswell, GD; Barozzi, I; Hong, SP; Trahearn, N; Spiteri, I; Stubbs, M; Burke, R; Stewart, A; Caravagna, G; Werner, B; Vlachogiannis, G; Maley, CC; Magnani, L; Valeri, N; Banerji, U; Sottoriva, A (2020-04-21)
      Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another ...
    • Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. 

      Sriskandarajah, P; De Haven Brandon, A; MacLeod, K; Carragher, NO; Kirkin, V; Kaiser, M; Whittaker, SR (2020-03-30)
      BACKGROUND:Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) ...
    • Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. 

      Harrison, PT; Vyse, S; Huang, PH (2020-04)
      Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) ...
    • Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. 

      Franco-Luzón, L; González-Murillo, Á; Alcántara-Sánchez, C; García-García, L; Tabasi, M; Huertas, AL; Chesler, L; Ramírez, M (2020-01-28)
      Celyvir (autologous mesenchymal cells -MSCs- that carry an oncolytic adenovirus) is a new therapeutic strategy for metastatic tumors developed by our research group over the last decade. There are limitations for studying ...
    • Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. 

      Lima, NC; Atkinson, E; Bunney, TD; Katan, M; Huang, PH (2020-05)
      Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. ...
    • Genomic landscape of platinum resistant and sensitive testicular cancers. 

      Loveday, C; Litchfield, K; Proszek, PZ; Cornish, AJ; Santo, F; Levy, M; Macintyre, G; Holryod, A; Broderick, P; Dudakia, D; Benton, B; Bakir, MA; Hiley, C; Grist, E; Swanton, C; Huddart, R; Powles, T; Chowdhury, S; Shipley, J; O'Connor, S; Brenton, JD; Reid, A; de Castro, DG; Houlston, RS; Turnbull, C (2020-05-04)
      While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and ...
    • Protein-altering germline mutations implicate novel genes related to lung cancer development. 

      Ji, X; Mukherjee, S; Landi, MT; Bosse, Y; Joubert, P; Zhu, D; Gorlov, I; Xiao, X; Han, Y; Gorlova, O; Hung, RJ; Brhane, Y; Carreras-Torres, R; Christiani, DC; Caporaso, N; Johansson, M; Liu, G; Bojesen, SE; Le Marchand, L; Albanes, D; Bickeböller, H; Aldrich, MC; Bush, WS; Tardon, A; Rennert, G; Chen, C; Byun, J; Dragnev, KH; Field, JK; Kiemeney, LF; Lazarus, P; Zienolddiny, S; Lam, S; Schabath, MB; Andrew, AS; Bertazzi, PA; Pesatori, AC; Diao, N; Su, L; Song, L; Zhang, R; Leighl, N; Johansen, JS; Mellemgaard, A; Saliba, W; Haiman, C; Wilkens, L; Fernandez-Somoano, A; Fernandez-Tardon, G; Heijden, EHFMVD; Kim, JH; Davies, MPA; Marcus, MW; Brunnström, H; Manjer, J; Melander, O; Muller, DC; Overvad, K; Trichopoulou, A; Tumino, R; Goodman, GE; Cox, A; Taylor, F; Woll, P; Wichmann, E; Muley, T; Risch, A; Rosenberger, A; Grankvist, K; Johansson, M; Shepherd, F; Tsao, M-S; Arnold, SM; Haura, EB; Bolca, C; Holcatova, I; Janout, V; Kontic, M; Lissowska, J; Mukeria, A; Ognjanovic, S; Orlowski, TM; Scelo, G; Swiatkowska, B; Zaridze, D; Bakke, P; Skaug, V; Butler, LM; Offit, K; Srinivasan, P; Bandlamudi, C; Hellmann, MD; Solit, DB; Robson, ME; Rudin, CM; Stadler, ZK; Taylor, BS; Berger, MF; Houlston, R; McLaughlin, J; Stevens, V; Nickle, DC; Obeidat, M; Timens, W; Artigas, MS; Shete, S; Brenner, H; Chanock, S; Brennan, P; McKay, JD; Amos, CI (2020-05-11)
      Few germline mutations are known to affect lung cancer risk. We performed analyses of rare variants from 39,146 individuals of European ancestry and investigated gene expression levels in 7,773 samples. We find a large-effect ...
    • Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells. 

      Carotenuto, P; Hedayat, S; Fassan, M; Cardinale, V; Lampis, A; Guzzardo, V; Vicentini, C; Scarpa, A; Cascione, L; Costantini, D; Carpino, G; Alvaro, D; Ghidini, M; Trevisani, F; Te Poele, R; Salati, M; Ventura, S; Vlachogiannis, G; Hahne, JC; Boulter, L; Forbes, SJ; Guest, R; Cillo, U; Said-Huntingford, I; Begum, R; Smyth, E; Michalarea, V; Cunningham, D; Rimassa, L; Santoro, A; Roncalli, M; Kirnkin, V; Clarke, P; Workman, P; Valeri, N; Braconi, C (2019-12-26)
      BACKGROUND AND AIMS:Changes in single microRNA (MIR) expression have been associated with chemo-resistance in Biliary Tract Cancer (BTC). However, a global assessment of the dynamic role of the microRNome has never been ...
    • Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. 

      Pancholi, S; Ribas, R; Simigdala, N; Schuster, E; Nikitorowicz-Buniak, J; Ressa, A; Gao, Q; Leal, MF; Bhamra, A; Thornhill, A; Morisset, L; Montaudon, E; Sourd, L; Fitzpatrick, M; Altelaar, M; Johnston, SR; Marangoni, E; Dowsett, M; Martin, L-A (2020-04-19)
      Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than ...
    • Measuring the distribution of fitness effects in somatic evolution by combining clonal dynamics with dN/dS ratios. 

      Williams, MJ; Zapata, L; Werner, B; Barnes, CP; Sottoriva, A; Graham, TA (2020-03-30)
      The distribution of fitness effects (DFE) defines how new mutations spread through an evolving population. The ratio of non-synonymous to synonymous mutations (dN/dS) has become a popular method to detect selection in ...
    • Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer 

      Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; Buus, R; Quang, LH; Han, PT; Khoa, PH; Dinh, NV; To, TV; Clemons, M; Holcombe, C; Osborne, C; Evans, A; Skene, A; Sibbering, M; Rogers, C; Laws, S; Noor, L; Smith, IE; Dowsett, M (2020-04)
    • Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. 

      Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; Warmuth-Metz, M; Sánchez Aliaga, E; Calmon, R; Hargrave, DR; Cañete, A; Massimino, M; Azizi, AA; Le Deley, M-C; Saran, F; Rousseau, RF; Zahlmann, G; Garcia, J; Vassal, G; Grill, J; Morgan, PS; Jaspan, T (2020-01-10)
      BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ...
    • Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. 

      Menezes, WPD; Silva, VAO; Gomes, INF; Rosa, MN; Spina, MLC; Carloni, AC; Alves, ALV; Melendez, M; Almeida, GC; Silva, LSD; Clara, C; da Cunha, IW; Hajj, GNM; Jones, C; Bidinotto, LT; Reis, RM (2020-02-20)
      The 5'-methylthioadenosine phosphorylase (MTAP) gene is located in the chromosomal region 9p21. MTAP deletion is a frequent event in a wide variety of human cancers; however, its biological role in tumorigenesis remains ...
    • Genetic predisposition for multiple myeloma. 

      Pertesi, M; Went, M; Hansson, M; Hemminki, K; Houlston, RS; Nilsson, B (2020-03)
      Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic ...
    • Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology. 

      Failmezger, H; Muralidhar, S; Rullan, A; de Andrea, CE; Sahai, E; Yuan, Y (2020-03)
      Despite the advent of immunotherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome. The successful application of immunotherapy requires in-depth understanding of the biological basis ...
    • Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes. 

      Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; Semiannikova, M; Newey, A; Barber, LJ; Mansfield, D; Hewitt, LC; Saito, Y; Davarzani, N; Starling, N; Melcher, A; Grabsch, HI; Gerlinger, M (2020-04-23)
      BACKGROUND:Gastric and gastro-oesophageal junction cancers (GCs) frequently recur after resection but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ...
    • Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. 

      Shah, V; Sherborne, AL; Johnson, DC; Ellis, S; Price, A; Chowdhury, F; Kendall, J; Jenner, MW; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; Davies, FE; Cook, G; Cairns, DA; Houlston, RS; Jackson, G; Kaiser, MF; on behalf of NCRI Haematology Clinical Studies Group (2020-03-11)
    • Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. 

      Cresswell, GD; Nichol, D; Spiteri, I; Tari, H; Zapata, L; Heide, T; Maley, CC; Magnani, L; Schiavon, G; Ashworth, A; Barry, P; Sottoriva, A (2020-03-27)
      Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving ...
    • Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. 

      Clarke, M; Mackay, A; Ismer, B; Pickles, JC; Tatevossian, RG; Newman, S; Bale, TA; Stoler, I; Izquierdo, E; Temelso, S; Carvalho, DM; Molinari, V; Burford, A; Howell, L; Virasami, A; Fairchild, AR; Avery, A; Chalker, J; Kristiansen, M; Haupfear, K; Dalton, JD; Orisme, W; Wen, J; Hubank, M; Kurian, KM; Rowe, C; Maybury, M; Crosier, S; Knipstein, J; Schuller, U; Kordes, U; Kram, DE; Snuderl, M; Bridges, L; Martin, AJ; Doey, LJ; Al-Sarraj, S; Chandler, C; Zebian, B; Cairns, C; Natrajan, R; Boult, JK; Robinson, SP; Sill, M; Dunkel, IJ; Gilheeney, SW; Rosenblum, MK; Hughes, D; Proszek, PZ; MacDonald, TJ; Preusser, M; Haberler, C; Slavc, I; Packer, R; Ng, H-K; Caspi, S; Popovic, M; Faganel Kotnik, B; Wood, MD; Baird, L; Davare, MA; Solomon, DA; Olsen, TK; Brandal, P; Farrell, M; Cryan, JB; Capra, M; Karremann, M; Schittenhelm, J; Schuhmann, MU; Ebinger, M; Dinjens, WNM; Kerl, K; Hettmer, S; Pietsch, T; Andreiuolo, F; Driever, PH; Korshunov, A; Hiddingh, L; Worst, BC; Sturm, D; Zuckermann, M; Witt, O; Bloom, T; Mitchell, C; Miele, E; Colafati, GS; Diomedi-Camassei, F; Bailey, S; Moore, AS; Hassall, TE; Lowis, SP; Tsoli, M; Cowley, MJ; Ziegler, DS; Karajannis, MA; Aquilina, K; Hargrave, DR; Carceller, F; Marshall, LV; von Deimling, A; Kramm, CM; Pfister, SM; Sahm, F; Baker, SJ; Mastronuzzi, A; Carai, A; Vinci, M; Capper, D; Popov, S; Ellison, DW; Jacques, TS; Jones, DTW; Jones, C (2020-04)
      Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases ...